ASMB (Assembly Biosciences) ROA %: -14.73% (As of Mar. 2026)


ASMB Assembly Biosciences Inc ASMB
32 GF Score
Price $26.74
! 3 Warning Signs
View Full Analysis

What is Assembly Biosciences ROA %?

Assembly Biosciences ASMB +10.25% 32 ROA % is -14.73% as of Mar. 2026. GuruFocus rates ASMB with a GF Score™ of 32/100. The stock has 3 warning signs investors should review. Among 1,422 Biotechnology companies, Assembly Biosciences ranks better than 77% on this metric.

ROA % is calculated as Net Income divided by its average Total Assets over a certain period of time. Assembly Biosciences's annualized Net Income for the quarter that ended in Mar. 2026 was $-36.32 Mil. Assembly Biosciences's average Total Assets over the quarter that ended in Mar. 2026 was $246.55 Mil. Therefore, Assembly Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 was -14.73%.

The historical rank and industry rank for Assembly Biosciences's ROA % or its related term are showing as below:

ASMB' s ROA % Range Over the Past 10 Years
Min: -63.58   Med: -35.15   Max: -3.25
Current: -3.5

During the past 13 years, Assembly Biosciences's highest ROA % was -3.25%. The lowest was -63.58%. And the median was -35.15%.

ASMB's ROA % is ranked better than
77% of 1422 companies
in the Biotechnology industry
Industry Median: -32.87 vs ASMB: -3.50

Assembly Biosciences  (NAS:ASMB) ROA % Explanation

ROA % measures the rate of return on the total assets (shareholder equity plus liabilities). It measures a firm's efficiency at generating profits from shareholders' equity plus its liabilities. ROA % shows how well a company uses what it has to generate earnings. ROA %s can vary drastically across industries. Therefore, ROA % should not be used to compare companies in different industries. For retailers, a ROA % of higher than 5% is expected. For example, Wal-Mart (WMT) has a ROA % of about 8% as of 2012. For banks, ROA % is close to their interest spread. A bank’s ROA % is typically well under 2%.

Similar to ROE, ROA % is affected by profit margins and asset turnover. This can be seen from the Du Pont Formula:

ROA %(Q: Mar. 2026 )
=Net Income/Total Assets
=-36.316/246.549
=(Net Income / Revenue)*(Revenue / Total Assets)
=(-36.316 / 32.852)*(32.852 / 246.549)
=Net Margin %*Asset Turnover
=-110.54 %*0.1332
=-14.73 %

Note: The Net Income data used here is four times the quarterly (Mar. 2026) net income data. The Revenue data used here is four times the quarterly (Mar. 2026) revenue data.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.


Be Aware

Like ROE, ROA % is calculated with only 12 months data. Fluctuations in the company's earnings or business cycles can affect the ratio drastically. It is important to look at the ratio from a long term perspective. ROA % can be affected by events such as stock buyback or issuance, and by goodwill, a company's tax rate and its interest payment. ROA % may not reflect the true earning power of the assets. A more accurate measurement is ROC % (ROC).

Many analysts argue the higher return the better. Buffett states that really high ROA % may indicate vulnerability in the durability of the competitive advantage.

E.g. Raising $43b to take on KO is impossible, but $1.7b to take on Moody's is. Although Moody's ROA % and underlying economics is far superior to Coca Cola, the durability is far weaker because of lower entry cost.


Assembly Biosciences ROA % Related Terms


Assembly Biosciences ROA % Historical Data

* Premium members only.

The historical data trend for Assembly Biosciences's ROA % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Assembly Biosciences ROA % Chart

Assembly Biosciences Annual Data
Trend Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23 Dec24 Dec25
ROA %
Get a 7-Day Free Trial Premium Member Only Premium Member Only -54.75 -63.58 -51.32 -31.39 -3.25

Assembly Biosciences Quarterly Data
Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25 Jun25 Sep25 Dec25 Mar26
ROA % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only -32.33 -45.38 -22.93 35.52 -14.73

ASMB vs MDXG, AGMB, TRAX: ROA % Comparison

For the Biotechnology subindustry, Assembly Biosciences's ROA %, along with its competitors' market caps and ROA % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Assembly Biosciences ROA % vs Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Assembly Biosciences's ROA % distribution charts can be found below:

* The bar in red indicates where Assembly Biosciences's ROA % falls into.


ASMB
32GF Score
Assembly Biosciences Inc ASMB
ROA % is just one metric. See GF Score™, valuation, warning signs, and more.
View Full Analysis

Assembly Biosciences ROA % Calculation

Assembly Biosciences's annualized ROA % for the fiscal year that ended in Dec. 2025 is calculated as:

ROA %=Net Income (A: Dec. 2025 )/( (Total Assets (A: Dec. 2024 )+Total Assets (A: Dec. 2025 ))/ count )
=-6.122/( (119.168+257.59)/ 2 )
=-6.122/188.379
=-3.25 %

Assembly Biosciences's annualized ROA % for the quarter that ended in Mar. 2026 is calculated as:

ROA %=Net Income (Q: Mar. 2026 )/( (Total Assets (Q: Dec. 2025 )+Total Assets (Q: Mar. 2026 ))/ count )
=-36.316/( (257.59+235.508)/ 2 )
=-36.316/246.549
=-14.73 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of annual ROA %, the net income of the last fiscal year and the average total assets over the fiscal year are used. In calculating the quarterly data, the Net Income data used here is four times the quarterly (Mar. 2026) net income data. ROA % is displayed in the 30-year financial page.

Frequently Asked Questions Learn more about ROA % →
What does a ROA % of -14.73% mean?
Assembly Biosciences (ASMB) has a ROA % of -14.73% as of Mar. 2026. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Assembly Biosciences and its competitors. According to the industry distribution chart, Assembly Biosciences ranks #327 out of 1422 companies in the Biotechnology industry, placing it in the top 23%.
Is Assembly Biosciences' ROA % too high?
Assembly Biosciences' current ROA % is -14.73%. Based on the distribution chart, Assembly Biosciences ranks #327 out of 1422 companies in the Biotechnology industry, which is in the top quartile — a strong position relative to peers. Overall, Assembly Biosciences has a GF Score™ of 32/100, reflecting its overall financial health beyond just this single metric.
How does Assembly Biosciences' ROA % compare to MDXG and AGMB?
According to the Biotechnology industry distribution chart, Assembly Biosciences ranks #327 out of 1422 companies for ROA %. This places Assembly Biosciences in the top 23% of its industry — outperforming the majority of peers. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good ROA % for a Biotechnology company?
A good ROA % depends on the Biotechnology industry context. However, ROA % should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high ROA % mean?
A high ROA % can signal that a stock is expensive relative to its fundamentals. Return on assets is the ratio of current-period net income to average two-period total assets. View historical data on Assembly Biosciences and its competitors. Assembly Biosciences's current ROA % is -14.73%. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Assembly Biosciences stock overvalued right now?
Assembly Biosciences (ASMB) has a current ROA % of -14.73%. The current ROA % is -14.73%. Assembly Biosciences' overall GF Score™ is 32/100 with 3 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is ROA % calculated?
ROA % is calculated from a company's financial statements. For Assembly Biosciences (ASMB), the current ROA % is -14.73% as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.

Assembly Biosciences Business Description

Other Exchanges V7B:Germany
Address Two Tower Place, 7th Floor, South San Francisco, CA, USA, 94080
Assembly Biosciences Inc is a clinical-stage biotechnology company. The Company's pipeline includes multiple clinical-stage investigational therapies, including: (1) two long-acting helicase-primase inhibitors (HPI) for the treatment of recurrent genital herpes; (2) an orally bioavailable hepatitis delta virus entry inhibitor; and (3) a potent next-generation capsid assembly modulator designed to disrupt the replication cycle of hepatitis B virus (HBV) at several key points. The Company's pipeline also includes a novel, oral broad-spectrum non-nucleoside polymerase inhibitor (NNPI) for the treatment of transplant-related herpesviruses.
32GF Score

Get the complete analysis for ASMB

ROA % is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.

$26.74
Price